Observational studies are often misunderstood in clinical trial budgeting. This article explains how to scope observational and non-interventional study budgets correctly, what costs should always be included, when additional procedures need to be coded, and how to handle common edge cases that create confusion during budget build.
Why do sponsors use central labs instead of local site laboratories? This article explains the real reason behind the central lab model in clinical trials, how it improves data consistency across global studies, the operational burden it creates at the site level, and why it matters for clinical trial budgeting and contract negotiations.
Central vs. local lab assumptions are one of the fastest ways to either overbuild or underbuild a clinical trial budget. This article breaks down how to code each setup correctly, how mixed lab models should be handled, and which assumptions must be documented to avoid costly rework, sponsor pushback, and site payment issues.
Clinical trial budgeting sits at the intersection of clinical, legal, finance, and operations. You will work with multiple stakeholders, each optimizing for different outcomes and understanding who owns what is critical for reducing friction, routing questions efficiently, and preventing delays during start-up.
